OXIGENE REPORTS CANCER DRUG TRIAL RESULTS

Oxigene has reported that clinical trials show that one of its drug candidates helped to significantly reduce blood flow to lung cancer tumors.

In a midstage clinical trial, the company said its drug candidate Combretastatin A4P, or CA4P, reduced blood flow to lung cancer tumors by 40 percent after three weeks when used with radiation treatment. Patients in the study had advanced non-small cell lung cancer, the most common type of lung cancer, where tumors could not be removed through surgery.

CA4P belongs to a class of drugs called vascular targeting agents, which restrict blood flow to solid tumors by attacking the vessels that feed them.